Physician profile
Bassem E Nasser
NPI 1881692952
$16,054.87
in general payments reported to CMS, 2019-2025
34 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,734 · 2020: $698 · 2021: $1,478 · 2022: $2,192 · 2023: $3,347 · 2024: $2,925 · 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,954.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,488.54 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $1,980.63 | 2019-2025 | Watchman Access System, Watchman, Lux-Dx Insertable Cardiac Monitor |
| Novartis Pharmaceuticals Corporation | $1,836.62 | 2019-2025 | |
| Amgen INC. | $1,036.65 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $994.64 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $910.40 | 2019-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $748.84 | 2019-2025 | Onpattro, Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $651.23 | 2022-2025 | Lifevest |
| Novo Nordisk INC | $537.22 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $435.31 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $425.31 | 2019-2024 | Farxiga, Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $424.47 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $416.10 | 2022-2025 | Verquvo, Capvaxive |
| Amarin Pharma, INC. | $313.72 | 2019-2021 | |
| Edwards Lifesciences Corporation | $283.54 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $270.24 | 2021-2025 | Micra, Reveal Linq |
| Astellas Pharma US INC | $227.62 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.96 | 2019-2025 | Jardiance |
| Scpharmaceuticals INC. | $201.41 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $191.13 | 2023-2024 | Inpefa |
| Biotronik INC. | $184.95 | 2020-2025 | Biomonitor, Amvia Edge |
| Esperion Therapeutics, INC. | $167.16 | 2023-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $144.55 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $124.22 | 2019-2025 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $123.55 | 2019 | |
| Abbott Laboratories | $95.98 | 2022-2023 | Amplatzer Amulet |
| Angiodynamics, INC. | $95.63 | 2022-2024 | Alphavac |
| Gilead Sciences, INC. | $91.87 | 2019 | |
| Bridgebio Pharma, INC. | $88.38 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $84.82 | 2019 | |
| Medtronic Vascular, INC. | $80.04 | 2019-2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $79.42 | 2022-2023 | Arcalyst |
| Baxter Healthcare | $59.25 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Impulse Dynamics (USA) INC. | $46.47 | 2023 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassem Nasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.